Method of inhibiting viral replication in eukaryotic cells and o

Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

435375, 514185, C12N 508

Patent

active

058495878

ABSTRACT:
The present invention is directed to methods which employ inhibition of the post-translational hypusine formation in the intracelluar protein eIF-5A, for the purpose of suppressing infections by viruses that parasitize eIF-5A so as to promote their own replication. Intentional inhibition of the post-translational formation of hypusine in infected host cells with compounds generically termed `hypusine inhibitors` not only selectively suppresses the production of viral proteins and of infectious viral particles, but also causes, particularly after hypusine inhibitor withdrawal, apoptosis in such virally-infected cells. Each of these methods, respectively, involves administering, to eukaryotic cells, tissues, or individuals, an agent which blocks the post-translational intracellular formation of hypusine, in an amount sufficient to: suppress biosynthesis of bioactive eIF-5A, suppress translational interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit biosynthesis of viral proteins of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, inhibit replication of Rev-dependent lentiviruses or of viruses dependent on interaction of eIF-5A with viral elements of nucleic acid and/or protein structure, and induce apoptosis of virally-infected cells. This agent can be a compound of Formulae I or II and derivatives thereof as follows: ##STR1## R.sub.1, R.sub.2, R.sub.3, and R.sub.4 each individually represent a hydrogen, an alkyl, alkenyl, or alkoxy group containing 1 to about 8 carbon atoms, an aryl, aralkyl, or cycloalkyl group containing about 5 to 12 carbon atoms, or a carboalkoxy or carbamyl group containing up to 8 carbon atoms, or a peptide or peptidomimetic moiety containing 10 to about 30 carbon atoms.

REFERENCES:
patent: 4246266 (1981-01-01), Undheim et al.
patent: 4585780 (1986-04-01), Hider et al.
patent: 4840958 (1989-06-01), Hider et al.
patent: 4908371 (1990-03-01), Moerker et al.
patent: 5185352 (1993-02-01), Aranda et al.
patent: 5256676 (1993-10-01), Hider et al.
patent: 5262409 (1993-11-01), Margolis et al.
patent: 5344846 (1994-09-01), Jakus et al.
patent: 5399566 (1995-03-01), Katano et al.
Herahko et al., "Results of Long-Term Deferiprone (LI) Therapy," Blood, (1994) (abstract).
Abbruzzese, A. et al. Biochim. et Biophys. Acta 1991. pp. 159-166.
Mitsuya, H. et al. 1990 Science vol. 249 pp. 1533-1544.
Park, M. H. et al. 1993 Biofactors vol. 4 (2) pp. 95-104.
Hashiguchi, et al., "Inhibition of Two Copper-Containing Enzymes, Tyrosinase and Dopamine .beta.-Hydroxylase, by L-Mimosine," Molecular Pharmacology, 13(2):362-367 (1977).
McCaffrey et al., "Specific Inhibition of eIF-5A and Collagen Hydroxylation by a Single Agent: Antiproliferative and Fibro-suppressive Effects on Smooth Muscle Cells from Human Coronary Arteries," Journal of Clinical Investigation, 95:446-455 (1995).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method of inhibiting viral replication in eukaryotic cells and o does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inhibiting viral replication in eukaryotic cells and o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting viral replication in eukaryotic cells and o will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1457143

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.